TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9050975
Drug: Lisinopril/hydrochlorothiazide
Normalized name: lisinopril/hydrochlorothiazide 20 mg-25 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril/hydrochlorothiazide
Study: 8288503
Drug: Ceftazidime 2
Normalized name: ceftazidime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 2 g tds
Study: 3506198
Drug: Solutions made
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solutions made in experimental villages
Study: 3506198
Drug: Solutions made
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solutions made in control villages
Study: 27315583
Drug: Fulvestrant (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulvestrant (500 mg)
Study: 9586668
Drug: Clodronate (1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate (1600 mg/day orally)
Study: 2686433
Drug: Intravenous diphenylhydantoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diphenylhydantoin (1,000 mg)
Study: 4926948
Drug: Control (Blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Blood Urea Concentration < 40 mg/100 ml)
Study: 4926948
Drug: Control (Blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Blood Urea Concentration 40-79 mg/100 ml)
Study: 4926948
Drug: Control (Blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Blood Urea Concentration ≥ 80 mg/100 ml)
Study: 7352850
Drug: Methadone hydrochloride
Normalized name: Methadone Hydrochloride
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methadone hydrochloride (60 mg daily)
Study: 7352850
Drug: Methadone hydrochloride
Normalized name: Methadone Hydrochloride
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methadone hydrochloride (increased doses)
Study: 30194663
Drug: Low-dose daily
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose daily prednisolone (0.2-0.3 mg/kg daily)
Study: 30194663
Drug: Standard alternate-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard alternate-day prednisolone (0.5-0.7 mg/kg alternate day)
Study: 21777100
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n=5, intact teeth without preparation or restoration)
Study: 17322141
Drug: Telmisartan (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (80 mg) with nisoldipine (10 mg)
Study: 8279942
Drug: 0.01 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01 mg/kg per hour of recombinant human IGF-I
Study: 3183852
Drug: Heparin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin and dipyridamole
Study: 27122214
Drug: 200 U
Normalized name: lipase 1200 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 U Botulinum‐A toxin injection
Study: 27122214
Drug: 300 U
Normalized name: lactase 3300 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 U Botulin‐A toxin injection
Study: 27122214
Drug: 200 U
Normalized name: lipase 1200 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 U Botulin‐A toxin injection
Study: 27122214
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of Botulinum‐A toxin
Study: 21485709
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (Xobix)
Study: 21485709
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (Melfax)
Study: 9492717
Drug: Extraamniotic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extraamniotic saline infusion
Study: 9492717
Drug: Intracervical application
Normalized name: eladocagene exuparvovec
DrugBank: Eladocagene exuparvovec (DB16780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical application of dinoprost 0.5 mg (prostaglandin)
Study: 8045656
Drug: Allopurinol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (600 mg before operation)
Study: 2692571
Drug: Maxepa (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxepa (20 capsules/day)
Study: 4908341
Drug: Amantadine hydrochloride
Normalized name: Amantadine Hydrochloride
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amantadine hydrochloride (100 mg, twice daily for 10 days)
Study: 23685830
Drug: Fibrin spray
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin spray (10 mL)
Study: 21864624
Drug: Matrix M™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matrix M™ adjuvanted virosomal H5N1 vaccine (1.5, 7.5, or 30 μg HA with 50 μg Matrix M™)
Study: 21864624
Drug: Virosomal H5N1
Normalized name: influenza, H5N1-1203
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virosomal H5N1 vaccine alone (30 μg HA)
Study: 11331165
Drug: 10 micro
Normalized name: Estradiol 10 microgram vaginal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micro g/kg neostigmine
Study: 11331165
Drug: 5 micro
Normalized name: Filter Connector 5 micron
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 micro g/kg neostigmine
Study: 9060525
Drug: Concurrent chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiation at weeks 1 to 4 (Group I)
Study: 8359923
Drug: CVD 103-HgR
Normalized name: Vibrio cholerae CVD 103-hgr strain live antigen
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD 103-HgR live oral cholera vaccine (5 x 10^9 CFU)
Study: 8359923
Drug: CVD 103-HgR
Normalized name: Vibrio cholerae CVD 103-hgr strain live antigen
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD 103-HgR live oral cholera vaccine (5 x 10^8 CFU)
Study: 3772096
Drug: Regular alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular alcohol consumption (0.8 g/kg per day)
Study: 31854112
Drug: One-month dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-month dual anti-platelet therapy (DAPT) with ticagrelor and aspirin followed by 23-month ticagrelor monotherapy
Study: 31854112
Drug: Experimental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment (ticagrelor monotherapy after DAPT)
Study: 31854112
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (standard DAPT followed by aspirin)
Study: 23106929
Drug: Concomitant psychotropic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant psychotropic medication use
Study: 16095144
Drug: Fluticasone propionate-salmeterol
Normalized name: Fluticasone Propionate/Salmeterol Xinafoate 55 MCG/1 ACTUATION-14 MCG/1 ACTUATION Inhalation Powder [FLUTICASONE PROPIONATE-SALMETEROL XINAFOATE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate-salmeterol (100/50 microg) twice daily for 12 weeks
Study: 16095144
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (100 microg) alone twice daily for 12 weeks
Study: 10490110
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) and UV-A combination treatment
Study: 10490110
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of FP and UV-A
Study: 26951772
Drug: Non-I-BiT games
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-I-BiT games (non-interactive binocular treatment)
Study: 20737524
Drug: Ondansetron (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (4 mg) plus fluoxetine (20 mg/day)
Study: 12639367
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg/day) plus placebo
Study: 18799202
Drug: Tamsulosin, 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin, 0.4 mg/d
Study: 10649929
Drug: Gluma Desensitizer
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gluma Desensitizer (rescue treatment)
Study: 23072081
Drug: Acupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture and Tuina therapy (group A)
Study: 15291377
Drug: Olmesartan (2.5-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan (2.5-80 mg once daily)
Study: 2006597
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (morphine, meperidine, ketobemidone)
Study: 6754485
Drug: khellin, orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: khellin, orally administered for 4 months with subsequent exposure to natural sunlight
Study: 12150168
Drug: Heptavalent pneumococcal
Normalized name: botulinum neurotoxin B immune FAB2
DrugBank: Equine Botulinum Neurotoxin B Immune FAB2 (DB13903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heptavalent pneumococcal conjugate vaccine
Study: 2503865
Drug: Parenteral glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral glucose by intravenous infusion
Study: 30900550
Drug: Multicomponent intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multicomponent intervention including a webinar, monthly reports of general practice-specific data for antibiotic prescribing, and decision support tools.
Study: 21392622
Drug: Idebenone (450/900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idebenone (450/900 mg/d or 1,350/2,250 mg/d)
Study: 17854242
Drug: Risperidone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (2 mg with dinner)
Study: 17854242
Drug: Quetiapine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (100 mg with dinner and 100 mg with breakfast)
Study: 15497673
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg sultamicillin tablets (Duobaktam 750 mg tablets)
Study: 15497673
Drug: 250 mg/5mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg/5mL sultamicillin suspension (Duobaktam 250 mg/5mL)
Study: 9399753
Drug: Methotrexate (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (12.5 mg weekly)
Study: 3665340
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not receiving anticonvulsant therapy)
Study: 3665340
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of prednisone and methylprednisolone
Study: 3665340
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of anticonvulsant therapy
Study: 3665340
Drug: Combination anticonvulsant
Normalized name: ANTICONVULSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination anticonvulsant therapy
Study: 24622830
Drug: Beer (4.7%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beer (4.7% vol, 400 ml)
Study: 24622830
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (13.7% vol, 200 ml)
Study: 24622830
Drug: Whisky (43.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whisky (43.5% vol, 100 ml)
Study: 24622830
Drug: Isotonic glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic glucose solution
Study: 24622830
Drug: Ethanol solutions
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol solutions of identical proof
Study: 24622830
Drug: Control ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control ethanol solutions
Study: 16311751
Drug: Biopsychosocial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biopsychosocial therapy (BT; n=31)
Study: 16311751
Drug: Conventional biomedical
Normalized name: hypromellose
DrugBank: Hypromellose (DB11075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional biomedical therapy (MT; n=33)
Study: 12747192
Drug: De Nol
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: De Nol triple therapy
Study: 8607332
Drug: Anticoagulant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant therapy (oral anticoagulants replaced with heparin from 6 to 12 weeks, vitamin K antagonists during second and third trimesters, heparin after 36 weeks until 10 days postpartum)
Study: 8607332
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not specified, but implied to be those not receiving anticoagulant therapy)
Study: 3894257
Drug: tiaprofenic acid
Normalized name: tiaprofenic acid
DrugBank: Tiaprofenic acid (DB01600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiaprofenic acid 600 mg daily
Study: 3894257
Drug: indomethacin 75
Normalized name: indomethacin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: indomethacin 75 mg daily
Study: 26409247
Drug: Free pregnancy
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free pregnancy test kits provided to CHWs (treatment group)
Study: 24628950
Drug: Hyperthermic intraperitoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperthermic intraperitoneal chemotherapy with oxaliplatin
Study: 24628950
Drug: Perioperative systemic
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative systemic chemotherapy and D1-D2 curative gastrectomy
Study: 15608044
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (group L, n=21) received i.v. saline
Study: 15608044
Drug: Perineural tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perineural tramadol group (group T, n=20) received i.v. saline and PCB with tramadol 1.5 mg kg(‐1)
Study: 15608044
Drug: Systemic tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic tramadol group (group IT, n=19) received i.v. tramadol 1.5 mg kg(‐1)
Study: 8530798
Drug: Tapering course
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapering course of prednisone (historical control)
Study: 23117723
Drug: Extended-duration enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-duration enoxaparin prophylaxis (40 mg daily for 28±4 days)
Study: 17034954
Drug: Oral progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral progesterone (400mg)
Study: 14523053
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg q.d.
Study: 14523053
Drug: Fenofibrate 200
Normalized name: fenofibrate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 200 mg q.d.
Study: 11271244
Drug: Acyclovir (3200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (3200 mg/day if creatinine clearance > 50 ml/min, intravenously for first 90 days)
Study: 3051990
Drug: Diltiazem (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (60 to 180 mg twice daily)
Study: 3051990
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 to 75 mg twice daily)
Study: 3051990
Drug: Diltiazem and
Normalized name: Diltiazem and enalapril only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem and Captopril in combination
Study: 17348223
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity ultrasound treatment
Study: 9309988
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate 100 micrograms twice daily
Study: 9309988
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate 500 micrograms twice daily
Study: 9309988
Drug: Oral fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluticasone propionate 20 mg once daily
Study: 8318328
Drug: Induction of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction of anaesthesia with propofol 3‐5 mg kg‐1 followed by maintenance with halothane and an appropriate regional block
Study: 8318328
Drug: Induction and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction and maintenance of anaesthesia with a computerized, target‐controlled infusion of propofol with a regional block
Study: 2882769
Drug: neostigmine 0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: neostigmine 0.07 mg kg‐1
Study: 2882769
Drug: edrophonium 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: edrophonium 0.8 mg kg‐1
Study: 27870712
Drug: Irosustat 40
Normalized name: Irosustat
DrugBank: Irosustat (DB02292)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irosustat 40 mg/d
Study: 16784014
Drug: Pharmacologic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic treatment (control group)
Study: 12915642
Drug: Glyburide/Metformin tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide/Metformin tablets (1.25/250 mg)
Study: 12915642
Drug: Glyburide (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide (2.5 mg)
Study: 12915642
Drug: Glyburide/Metformin tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide/Metformin tablets
Study: 8750803
Drug: 1 alpha‐hydroxyvitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 alpha‐hydroxyvitamin D3 (1 alpha‐OHD3) at a dose of 0.05 microgram/kg per day for 1 year
Study: 31152038
Drug: Colchicine 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.01 mg/day
Study: 31152038
Drug: Colchicine 0.005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.005 mg/day
Study: 26996228
Drug: Increased intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased intake of fruits and vegetables (≥500 g daily)
Study: 24706088
Drug: Flecainide (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide (150 or 100 mg/day according to body weight)
Study: 24706088
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no antiarrhythmic drugs)
Study: 9069612
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus MLT (20 mg/day p.o. in the evening)
Study: 3082163
Drug: Omnipaque 350
Normalized name: Omnipaque 350
DrugBank: Iohexol (DB01362)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omnipaque 350 mg l/ml (iohexol)
Study: 3082163
Drug: Hexabrix 320
DrugBank: Ioxaglic acid (DB09313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hexabrix 320 mg l/ml (ioxaglate)
Study: 24070115
Drug: Low-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose interferon suppository (1,000 IU) administered daily for 24 weeks
Study: 15947913
Drug: Levobupivacaine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 5 mg/ml
Study: 15947913
Drug: Levobupivacaine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 2.5 mg/ml
Study: 15947913
Drug: Lidocaine 10
Normalized name: lidocaine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 10 mg/ml with adrenaline
Study: 10655439
Drug: FAC followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FAC followed by high-dose chemotherapy (cyclophosphamide, etoposide, and cisplatin with autologous hematopoietic stem cell support)
Study: 9289427
Drug: Hormonal treatment
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal treatment and spasmolytic drugs for patients with threatened abortion
Study: 1671631
Drug: Sulphasalazine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphasalazine plus prednisone (6 g/d sulphasalazine, 30 mg/d prednisone initially, tapered to 10 mg/d after 8 weeks)
Study: 1671631
Drug: Sulphasalazine alone
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulphasalazine alone (6 g/d, placebo for prednisone)
Study: 29100262
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (cold drink + dexamethasone)
Study: 22322141
Drug: Biobrane® and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biobrane® and autologous cell suspension using the ReCell® kit
Study: 22322141
Drug: Local standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local standard treatment (Intrasite™, Acticoat™, and Duoderm(®) dressings every 2‐3 days) with surgery at 10 days
Study: 16170293
Drug: Metoclopramide infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide infusion supplemented by vitamin B12 complex
Study: 12826840
Drug: 6% HES
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% HES 130/0.4 at a dose of up to 50 ml/kg
Study: 12826840
Drug: 6% HES
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% HES 200/0.5 at a dose of up to 33 ml/kg
Study: 8938603
Drug: Pharmacological agents
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological agents designed to augment functional recovery of the injured spinal cord
Study: 8938603
Drug: New drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: New drugs evaluated through scientific and regulatory processes
Study: 8938603
Drug: Classification scheme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classification scheme based on FDA regulations for drug availability
Study: 1510257
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution (3 mL)
Study: 1510257
Drug: 1.5% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% lidocaine with epinephrine 1:200,000 (1 mL, diluted to 3 mL with normal saline)
Study: 1510257
Drug: 1.5% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% lidocaine with epinephrine 1:200,000 (2 mL, diluted to 3 mL with normal saline)
Study: 1510257
Drug: 1.5% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% lidocaine with epinephrine 1:200,000 (3 mL, diluted to 3 mL with normal saline)
Study: 30015544
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy (BLT) with light glasses for 4 weeks
Study: 30015544
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy (BLT) for 4 weeks
Study: 22829023
Drug: Telmisartan alone
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan alone or in combination with Ramipril